出現糖尿病護理
成立一年
2013年階段
商業計劃競賽 |活著總了
9.73美元缺失:出現糖尿病護理的產品演示和案例研究
促進你的產品提供技術買家。
達到1000年代的買家使用CB的見解來確定供應商,演示產品,188bet游戏做出購買決定。
缺失:出現糖尿病護理的產品&微分器
不要讓你的產品被跳過。買家使用我們的供應商排名名單公司和驅動(rfp)請求建議。
糖尿病護理專家集合包含持久性有機汙染物
專家集合是analyst-curated列表,突出了公司你需要知道的最重要的技術空間。
持久性有機汙染物包括糖尿病護理4專家集合,包括醫療設備。
醫療設備
8633件
公司發展醫療器械(每IMDRF的“醫療器械”的定義)。包括軟件、lab-developed測試(LDTs)和組合產品。*列更新盡可能經常。
糖尿病
2121件
數字醫療
10363件
數字健康收藏品包括供應商開發軟件、平台、傳感器和機器人硬件,在醫療健康數據基礎設施和tech-enabled服務。列表中不包括製藥/生物製藥、測序儀器,基因編輯和輔助技術。
它的健康
7901件
最新的出現糖尿病護理新聞
2022年1月25日,
分享這篇文章提供的新聞分享本文澤西城,新澤西州2022年1月25日InsightAce分析從pvt ltd .)宣布釋放一個市場評估報告”“全球智能手機操作/新一代葡萄糖監控市場趨勢、行業競爭分析、收入和預測到2030年。”Get the Sample Pages: https://www.insightaceanalytic.com/request-sample/1196 According to the latest research by InsightAce Analytic, the Global Smartphone Operated/Next-Generation Glucose Monitor Market was valued at US$ 3.50 Billion in 2021, and it is expected to reach US$ 14.91 Billion by 2030, with a CAGR of 17.8% during the forecast period of 2022-2030. Glucose monitoring devices are used to detect blood glucose levels in the body, and the next-generation continuous glucose monitors are the easiest way to manage and control diabetes. These systems provide details about the medications, diseases, diet, and medicine reminders. The various features such as real-time data analysis, low cost, and easy availability of smartphone-operated glucose monitors will compel the growth of the smartphone-operated/next-generation glucose monitor market during the forecast period. Furthermore, factors such as the growing aging population, high prevalence of diabetes among all ages, fast adoption of innovative technologies, changing lifestyle patterns, increasing overweight & obesity among the public, demand for less invasive procedures, and the increasing healthcare expenditure are expected to fuel the market growth. According to the WHO, around 3.4 Billion individuals worldwide die due to high blood glucose annually. About 80% of these deaths occur in low- and middle-income countries, and almost 50% of individuals are under 70 years. WHO also estimated that diabetes deaths will double between 2005 and 2030. Therefore, increasing cases of diabetes are anticipated to propel the demand for smartphone operated/next-generation glucose monitor market in the coming years. However, the lack of awareness among patients about modern healthcare devices and stringent reimbursement policies for advanced systems hinder the smartphone-operated/next-generation glucose monitor market growth in the future. North America is expected to dominate the smartphone-operated/next-generation glucose monitor market during the forecast period (2019-2030), followed by Europe, owing to the high prevalence of diabetes and the fast adoption of advanced technologies. On the other side, Asia Pacific is likely to witness significant growth in the next few years due to the growing elderly population, increasing diabetes cases, and the rising innovations in the glucose monitor systems. Request for ToC : https://www.insightaceanalytic.com/customisation/1196 Major market players operating in the smartphone-operated/next-generation glucose monitor market include Health Arx Technologies Pvt. Ltd (India), myDario (US), iHealth Labs, Inc (US), KETO-MOJO (US), LifeScan IP Holdings, LLC (US), Ascensia Diabetes Care (Switzerland), Glooko, Inc (US), Dexcom, Inc (US), Roche Diabetes Care (US), ForeCare, Inc (US), Informed Data Sytems Inc (US), One Drop (US), Amanda Health Inc (US, Big Foot Medical Inc (US), Pops Diabetes Care Inc (US), HealthifyMe (Bengaluru), Intruity Medical, Inc (US), Health25ync (Taiwan), myDiabby Healthcare (France), Symbiome (US), Senseonics Holdings, Inc. (US), Diabnext (France), Diabeto Medtech India Pvt (India), Biosense Technology Pvt Ltd (India), among others. Key developments in the market: In October 2021, LifeScan (US), a world leader in blood glucose monitoring, launched OneTouch Solutions, an eCommerce site offering a convenient and comprehensive choice of personalized wellness programs to help people manage diabetes. In August 2020, Senseonics Holdings, Inc. (US), a medical technology company developing continuous glucose monitoring (CGM) systems for people with diabetes, partnered with Ascensia Diabetes Care through a commercialization and collaboration agreement. Through this collaboration, Ascensia worldwide distributes Senseonics' Eversense CGM systems. The Eversense brand of CGM systems is indicated for continually measuring glucose levels in persons aged 18 and older with diabetes. Market Segments Diabetes Monitoring Devices Single-Use Home Settings North America U.S. Germany India Brazil South Africa
出現糖尿病護理常見問題(FAQ)
持久性有機汙染物糖尿病護理是何時成立的?
出現糖尿病護理成立於2013年。
出現糖尿病護理的總部在哪裏?
出現糖尿病護理的總部位於6770年靜大道,200套房,靜。
持久性有機汙染物糖尿病護理的最新一輪融資是什麼?
出現糖尿病護理的最新一輪融資商業計劃競賽。
持久性有機汙染物糖尿病護理提高了多少錢?
出現糖尿病護理提高了總共9.73美元。
出現糖尿病護理的投資者是誰?
持久性有機汙染物糖尿病護理的投資者包括AngelMD最佳創業競爭,醫學技術創新者,即插即用加速器,30個企業,飛點產業和4。
發現正確的解決方案為您的團隊
CB見解188bet游戏科技市場情報平台分析數百萬數據點在供應商、產品、合作關係,專利來幫助您的團隊發現他們的下一個技術解決方案。